Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-MNA in Basal Cell Carcinoma
NCT03646188Phase 1Terminated
- Sponsor
- SkinJect
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin in basal cell carcinoma (BCC) (5 arms), sponsored by SkinJect. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Jun 2020; status: terminated.
02
Drugs
doxorubicin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03646188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646188.